Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Pharvaris NV (OQ:PHVS)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: J.H. Oortweg 21
LEIDEN 2333 CH
Tel: N/A
Website: https://pharvaris.com
IR: See website
Key People
Berndt Modig
Chief Executive Officer, Co-Founder, Executive Director
Jochen Knolle
Co-Founder, Chief Operating Officer, Chief Scientific Officer
Hans Schikan
Co-Founder, Non-Executive Director
Anne Lesage
Co-Founder, Chief Early Development Officer
David W. Nassif
Chief Financial Officer
Anna Nijdam
Head of Finance, Principal Accounting Officer
Morgan Conn
Chief Business Officer
Peng Lu
Chief Medical Officer
Wim Souverijns
Chief Community Engagement and Commercial Officer
Business Overview
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Financial Overview
For the nine months ended 30 September 2024, Pharvaris NV revenues was not reported. Net loss increased 46% to EUR99.5M. Higher net loss reflects Research & Development Expense - Bal increase of 45% to EUR48.4M (expense), Selling, General & Administrative Expens increase of 63% to EUR20M (expense), Personnel expenses increase of 40% to EUR19M (expense).